logo-loader
Amphion Innovations PLC

Amphion Innovations uses Polarean stake to settle loan facility

Snapshot

Amphion Innovations provides “concentrated but well-managed portfolio” in high growth sectors

Amphion Innovations PLC -

Quick facts: Amphion Innovations PLC

Price: 0.15 GBX

Market: AIM
Market Cap: £314.96 k
Follow
  • Investment firm focused on medical and technology sectors

  • Concentrated portfolio of companies

 

What Amphion does

Amphion Innovations PLC (LON:AMP) is an investment company that focuses on helping build companies in the medical and technology sectors.

The firm currently has shareholdings in seven partner companies that are developing technologies targeting what it says are “substantial commercial marketplaces”.

What Amphion owns

The company has stakes in six partner companies;

1. Axcess International – 15.07% stake – provides wireless systems that help monitor business activity in real-time in sectors such as transport and security

2. FireStar Software – 11.86% stake – develops software the helps companies to integrate and exchange data electronically in a private, secured structure

3.  PrivateMarkets – 25.33% stake – an online marketplace that links buyers and sellers of physical commodities such as gold and copper

4. WellGen – 24.34% stake – develops foods designed to help treat inflammation-based illnesses. The company also has a proprietary black tea extract that has been demonstrated to improve performance and recovery benefits such as a reduction in muscle soreness and reduced recovery time

5. DataTern – 100% stake – a company established for Amphion to commercialise intellectual properties that originate from its portfolio companies

6. Motif Bio PLC (LON:MTFB) – 6.78% stake – an antibiotic developer focusing on diseases caused by drug-resistant bacteria

Inflexion points

  • Company recently paid back a loan facility through sale of its stake in Polarean
  • In October, Amphion said it remains highly cash-constrained with shares suspended

 

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Amphion Innovations PLC named herein, including the promotion by the Company of Amphion Innovations PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

MaxCyte offering exposure to 'explosive growth' in cell therapy and cellular...

Proactive Research analyst Emma Ulker gives her view on the work MaxCyte Inc's (LON:MXCT) doing in the area of cell and gene therapy. MXCT has more than 80 licensed programmes including more than 45 licensed for clinical use. They've announced seven clinical/commercial partnership deals...

1 week, 2 days ago

2 min read